Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Constantine E Kosmas, Maria D Bousvarou, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta & Eliscer Guzman. (2022) Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. Clinical Pharmacology: Advances and Applications 14, pages 49-59.
Read now
Read now
James Underberg, Peter P. Toth & Fatima Rodriguez. (2022) LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgraduate Medicine 134:8, pages 752-762.
Read now
Read now
Constantine E Kosmas, Andreas Skavdis, Andreas Sourlas, Evangelia J Papakonstantinou, Edilberto Peña Genao, Rogers Echavarria Uceta & Eliscer Guzman. (2020) Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clinical Pharmacology: Advances and Applications 12, pages 191-202.
Read now
Read now
Articles from other publishers (23)
Catherine DePhillips. (2023) The Role of RNA Interference Therapeutics in Hypercholesterolemia and Implications for Practice. The Journal for Nurse Practitioners 19:6, pages 104619.
Crossref
Crossref
Wolfgang Koenig, Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, Gregory G. Schwartz, R. Scott Wright, Lorena Garcia Conde, Jackie Han & Frederick J. Raal. (2023) Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. American Journal of Preventive Cardiology 14, pages 100503.
Crossref
Crossref
Niki Katsiki, Michal Vrablik, Maciej Banach & Ioanna Gouni-Berthold. (2023) Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals 16:4, pages 577.
Crossref
Crossref
Xiu Hong Yang, Bao Long Zhang, Yun Cheng, Shun Kun Fu & Hui Min Jin. (2023) Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis. Atherosclerosis 371, pages 21-31.
Crossref
Crossref
Oluwakemi Ebenezer, Pietro Comoglio, Gane Ka-Shu Wong & Jack A. Tuszynski. (2023) Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia. International Journal of Molecular Sciences 24:4, pages 4019.
Crossref
Crossref
Yan Zhou, Xueping Zhu, Huan Wang, Chenglin Duan, Hanming Cui, Jingjing Shi, Shuai Shi, Guozhen Yuan & Yuanhui Hu. (2023) The Role of VEGF Family in Lipid Metabolism. Current Pharmaceutical Biotechnology 24:2, pages 253-265.
Crossref
Crossref
Yufei Pan, Xinyang Zhou & Zhenjun Yang. 2023. Nucleic Acids in Medicinal Chemistry and Chemical Biology. Nucleic Acids in Medicinal Chemistry and Chemical Biology
373
427
.
Alexander Curreri, Disha Sankholkar, Samir Mitragotri & Zongmin Zhao. (2022)
RNA
therapeutics in the clinic
. Bioengineering & Translational Medicine 8:1.
Crossref
Crossref
S. K. Zyryanov & O. I. Butranova. (2022) New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy. Russian Journal of Cardiology 27:11, pages 5271.
Crossref
Crossref
Shuai Qu, Renfa Liu, Nisi Zhang, Yunxue Xu, Xiuli Yue & Zhifei Dai. (2022) Non-viral nucleic acid therapeutics: Revolutionizing the landscape of atherosclerotic treatment. Nano Today 45, pages 101514.
Crossref
Crossref
Lamija Ferhatbegović, Denis Mršić, Sabina Kušljugić & Belma Pojskić. (2022) LDL-C: The Only Causal Risk Factor for ASCVD. Why Is It Still Overlooked and Underestimated?. Current Atherosclerosis Reports 24:8, pages 635-642.
Crossref
Crossref
Anna Martin, Sonja Lang, Tobias Goeser, Münevver Demir, Hans-Michael Steffen & Philipp Kasper. (2022) Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Current Atherosclerosis Reports 24:7, pages 533-546.
Crossref
Crossref
Paul T. McIntosh & Christopher T. Doughty. (2022) Toxic Myopathies. Current Treatment Options in Neurology 24:6, pages 217-239.
Crossref
Crossref
Kalina Paunovska, David Loughrey & James E. Dahlman. (2022) Drug delivery systems for RNA therapeutics. Nature Reviews Genetics 23:5, pages 265-280.
Crossref
Crossref
Juan Vicente-Valor, Xandra García-González, Sara Ibáñez-García, María Esther Durán-García, Ana de Lorenzo-Pinto, Carmen Rodríguez-González, Irene Méndez-Fernández, Juan Carlos Percovich-Hualpa, Ana Herranz-Alonso & María Sanjurjo-Sáez. (2022) PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort. Biomedicine & Pharmacotherapy 146, pages 112519.
Crossref
Crossref
S.A. Boitsov, M.A. Piradov, M.M. Tanashyan, I.A. Voznyuk, M.V. Yezhov, E.V. Oshchepkova, I.V. Sergienko, N.A. Shamalov, Ya.B. Skiba & S.N. Yanishevskiy. (2022) Topical issues of adequate control of dyslipidemia in the prevention of acute and recurrent cerebral circulatory disorders of ischemic type. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:5, pages 7.
Crossref
Crossref
A.B. Sumarokov. (2022) Inclisiran — lipid-lowering drug using RNA therapy. Hypolipidemic potential. Kardiologicheskii vestnik 17:4, pages 32.
Crossref
Crossref
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, Piotr Dobrowolski, Dariusz Dudek, Krzysztof Dyrbuś, Mariusz Gąsior, Piotr Jankowski, Jacek Jóźwiak, Longina Kłosiewicz-Latoszek, Irina Kowalska, Maciej Małecki, Aleksander Prejbisz, Michał Rakowski, Jacek Rysz, Bogdan Solnica, Dariusz Sitkiewicz, Grażyna Sygitowicz, Grażyna Sypniewska, Tomasz Tomasik, Adam Windak, Dorota Zozulińska-Ziółkiewicz & Barbara Cybulska. (2021) 2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna 57:1, pages 1-99.
Crossref
Crossref
Lale Tokgozoglu & Meral Kayikcioglu. (2021) Familial Hypercholesterolemia: Global Burden and Approaches. Current Cardiology Reports 23:10.
Crossref
Crossref
Marcio H. Miname, Viviane Z. Rocha & Raul D. Santos. (2021) The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. Current Atherosclerosis Reports 23:8.
Crossref
Crossref
Stanley T. Crooke, Brenda F. Baker, Rosanne M. Crooke & Xue-hai Liang. (2021) Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery 20:6, pages 427-453.
Crossref
Crossref
Piotr Pęczek, Mateusz Leśniewski, Tomasz Mazurek, Lukasz Szarpak, Krzysztof J. Filipiak & Aleksandra Gąsecka. (2021) Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia. Life 11:6, pages 466.
Crossref
Crossref
Antonio Gordillo-Moscoso, Rafael Almendra-Pegueros & Úrsula Medina. (2021) Presente y futuro del tratamiento hipolipemiante, nuevas moléculas a la vista. Cardiovascular and Metabolic Science 32:S3, pages 225-230.
Crossref
Crossref